WBQ5187

clioquinol-moracin M hybrid

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

1.	Cognitive Dysfunction 12/18/2019 - "WBQ5187, a Multitarget Directed Agent, Ameliorates Cognitive Impairment in a Transgenic Mouse Model of Alzheimer's Disease and Modulates Cerebral β-Amyloid, Gliosis, cAMP Levels, and Neurodegeneration."
2.	Gliosis 12/18/2019 - "Furthermore, WBQ5187 notably reduced cerebral β-amyloid pathology, gliosis, and neuronal cell loss and increased the levels of cAMP in the hippocampus of these mice. " 12/18/2019 - "WBQ5187, a Multitarget Directed Agent, Ameliorates Cognitive Impairment in a Transgenic Mouse Model of Alzheimer's Disease and Modulates Cerebral β-Amyloid, Gliosis, cAMP Levels, and Neurodegeneration."
3.	Alzheimer Disease (Alzheimer's Disease) 12/18/2019 - "Previously, we designed, synthesized, and evaluated a series of quinolone-benzofuran derivatives as multitargeted anti-Alzheimer's disease (anti-AD) compounds, and we discovered that WBQ5187 possesses superior anti-AD bioactivity. " 12/18/2019 - "WBQ5187, a Multitarget Directed Agent, Ameliorates Cognitive Impairment in a Transgenic Mouse Model of Alzheimer's Disease and Modulates Cerebral β-Amyloid, Gliosis, cAMP Levels, and Neurodegeneration."
4.	Vomiting 12/18/2019 - "The surrogate measures of emesis indicated that WBQ5187 had no effect at its cognitive effective doses. "